Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | RAD52 | P43351 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4949018 | 0.87 | ALDH1A1 (0.37) | MAPTGAASMN1; SMN2KDM4E | |
| SCHEMBL24826477 | 0.83 | RIPK1 (0.32) | RIPK1TMEM97SIGMAR1KCNH2 | |
| SCHEMBL2989704 | 0.79 | RIPK1 (0.32) | GAARIPK1 | |
| SCHEMBL2991734 | 0.77 | NOTUM (0.43) | RIPK1TMEM97SIGMAR1KCNH2 | |
| SCHEMBL7485284 | 0.74 | KDM4E (0.39) | MAPTGAASMN1; SMN2RIPK1KDM4E | |
| SCHEMBL4947251 | 0.71 | ALDH1A1 (0.38) | MAPTGAASMN1; SMN2KDM4E | |
| SCHEMBL15427984 | 0.71 | CYP3A4 (0.39) | MAPTGAASMN1; SMN2 | |
| SCHEMBL18252838 | 0.70 | EZH2 (0.40) | TMEM97SIGMAR1KCNH2 | |
| SCHEMBL24823633 | 0.69 | CSF1R (0.36) | RIPK1 | |
| Hydrochloric Acid SCHEMBL11486507 | 0.66 | MAPT (0.34) | MAPTGAASMN1; SMN2KDM4ERAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105657-A1 | Compounds, Process for their Preparation, Intermediates, Pharmaceutical Compositions and their use in the Treatment of 5-HT6 Mediated Disorders such as Alzheimer's Disease, Cognitive Disorders, Cognitive Impairment Associated with Schizophrenia, Obesity and Parkinson's Disease | ASTRAZENECA AB (SE) | 2010-04-29 | — | — | US | disclosed |
| EP-1910321-A1 | NEW COMPOUNDS, PROCESS FOR THEIR PREPARATION, INTERMEDIATES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OF 5-HT6 MEDIATED DISORDERS SUCH AS ALZHEIMER'S DISEASE, COGNITIVE DISORDERS, COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA, OBESITY AND PARKINSON'S DISEASE | AstraZeneca AB (SE) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007004959-A1 | NEW COMPOUNDS, PROCESS FOR THEIR PREPARATION, INTERMEDIATES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OF 5-HT6 MEDIATED DISORDERS SUCH AS ALZHEIMER'S DISEASE, COGNITIVE DISORDERS, COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA, OBESITY AND PARKINSON'S DISEASE | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105657-A1 | Compounds, Process for their Preparation, Intermediates, Pharmaceutical Compositions and their use in the Treatment of 5-HT6 Mediated Disorders such as Alzheimer's Disease, Cognitive Disorders, Cognitive Impairment Associated with Schizophrenia, Obesity and Parkinson's Disease | HTR6, HTR3B, HTR5A | HTR4 7/4885MAPT 87/4885GAA 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.